Yale Canine Cancer Vaccine
Saturday, Oct 3, 2020
1:00pm – 2:30pm EST (Zoom)
Professor Mark Mamula
Yale University School of Medicine
Canine osteosarcoma is the most common primary skeletal tumor in dogs. Despite relatively aggressive standard-of-care treatment consisting of amputation and adjuvant chemotherapy, survival times are limited to a median of 9-11 months.
In this talk, Dr. Mark Mamula will describe a new Epidermal Growth Factor Receptor (EGFR) peptide-based cancer vaccine. He will review his preliminary findings, including safety and efficacy data from a clinical study involving canine patients with osteosarcoma, hemangiosarcoma, and other malignancies linked to EGFR over-expression.
The seminar is followed by a Q&A session.